Reporter brief
Fisetin with PRP and losartan for hip impingement: pilot RCT results not reported
What happened
This was a pilot RCT investigating whether the senolytic agent fisetin, combined with platelet-rich plasma (PRP) and losartan, could improve outcomes in patients undergoing hip arthroscopy for femoroacetabular impingement and labral tear. The study aimed to assess clinical outcomes, safety, and markers of senescence and fibrosis, but the abstract reports study objectives and design only—no results are presented.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients suffering from femoroacetabular impingement and labral tear who are planning to undergo hip arthroscopy, recruited from The Steadman Clinic
- Design
- Rct
- Sample
- —
- Journal
- Steadman Philippon Research Institute
- Published
- Apr 16, 2024
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.